“sarepta-therapeutics” Archives

in
Entry Author Date Location
Ed Kaye on Sarepta’s Duchenne Quest, Rising to CEO & His New Startup 11/20/17 Boston
With $40M for Exonics, Duchenne’s Gene Therapy, CRISPR Race Heats Up 11/08/17 Boston
Biotech Roundup: Opioid News, ASH Preview, Boston Bio IPOs & More 11/03/17 National
FDA Panel Pans PTC’s Audacious Plan to Force Vote on Duchenne Drug 09/28/17 New York
Alnylam Data Puts a Nobel Discovery One Step Closer to Approved Drug 09/20/17 Boston
Going Big or Against the Tide: Meet the Big Idea & Contrarian Award Finalists 09/14/17 Boston
Bio Roundup: RNAi Drama, Immunotherapy Data, Lasker Winners & More 09/08/17 National
Startup Builders, IPO Closers & More: Meet Xconomy’s CEO Award Finalists 08/10/17 Boston
Bio Roundup: GOP Drama, Immunotherapy Setbacks, Pharma Revamps 07/28/17 National
Bio Roundup: Senate Drama, A.I. Stories, Data Dives, Shkreli & More 06/30/17 National
Stifling Immigration Is “Retrograde”: Highlights From “What’s Hot” 05/17/17 Boston
Last Chance to Snag a Ticket for What’s Hot in Boston Biotech 05/10/17 Boston
Analysts Expect Payer Pushback as PTC Sets $35K Price For Duchenne Drug 05/08/17 New York
Grab Your Ticket for What’s Hot in Boston Biotech on May 11th 05/03/17 Boston
After Sarepta’s Surprising FDA Nod, CEO Kaye Plans to Resign 04/28/17 Boston
Duchenne, SMA, and the Rise of Patient Power at “What’s Hot” on May 11 04/27/17 Boston
Check Out What’s Hot in Boston Biotech on May 11: Saver Rate Ends Today 04/06/17 Boston
Next Stop on Father’s Duchenne Quest: Wall Street? Solid Raises $50M 03/30/17 Boston
After a Clinical Trial Death, FDA OKs New Tests of Akashi’s Duchenne Drug 03/22/17 Boston
For $140M, PTC Gets Duchenne Drug and a Pricing Controversy from Marathon 03/16/17 New York
Nonprofit Seeds Exonics to Fund Push For CRISPR Duchenne Treatment 02/27/17 Boston
Bio Roundup: Trump Backlash, Verdine Plans, Sarepta Sale & More 02/24/17 National
Cashing in On Duchenne Approval, Sarepta Sells Voucher to Gilead For $125M 02/21/17 Boston
His Gene Therapy Near Approval, Spark CEO Wonders: What Price Vision? 02/16/17 New York
Anthem Caps Coverage Of Biogen Spine Drug Despite Wide FDA Approval 01/24/17 Boston
Biotech Roundup: JPM Deals, Gender Diversity, PCSK9 Battle & More 01/13/17 National
Notes From The JPM ’17 Vortex: Trump, Rainstorms & The Price You Pay 01/13/17 National
CEO Kaye Details Insurance Battle As Sarepta Launches Duchenne Drug 01/10/17 Boston
Families Fret As Insurers Mull Biogen’s $750K Spine Disease Drug 01/06/17 National
Biogen Sets $750,000 Initial Price For First-Ever Spinal Atrophy Drug 12/28/16 Boston
Page 1 of 5 next page »